Join to View Full Profile
125 Queens Rd Ste 610Charlotte, NC 28204
Phone+1 980-302-6600
Fax+1 980-302-6605
Dr. Zausner Skarbnik is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
City of Hope Comprehensive Cancer CenterAdult Hematopoietic Stem Cell Transplantation, 2013 - 2014
Temple University Hospital-Fox Chase Cancer CenterFellowship, Hematology and Medical Oncology, 2010 - 2013
Icahn School of Medicine at Mount Sinai/Morningside/WestResidency, Internal Medicine, 2007 - 2010
Universidade de Sao Paulo Faculty of MedicineClass of 2003
Certifications & Licensure
CA State Medical License 2013 - Present
NC State Medical License Active through 2025
DC State Medical License 2018 - 2020
NJ State Medical License 2014 - 2019
PA State Medical License 2010 - 2014
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence Start of enrollment: 2016 Jun 07
Publications & Presentations
PubMed
- 2 citationsConsensus recommendations from the 2024 Lymphoma Research Foundation workshop on treatment selection and sequencing in CLL or SLL.Jacob D Soumerai, Jacqueline Barrientos, Inhye Ahn, Catherine Coombs, Douglas Gladstone
Blood Advances. 2025-03-11 - Treatment Effectiveness of Venetoclax-Based Therapy After Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study.Nilanjan Ghosh, Toby A Eyre, Jennifer R Brown, Nicole Lamanna, Beenish S Manzoor
American Journal of Hematology. 2025-03-01 - Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLL.Adam S Kittai, Ying Huang, Sarah Miller, John N Allan, Seema A Bhat
Blood Cancer Journal. 2025-02-20
Abstracts/Posters
- Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel TherapiesAlan Skarbnik, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Allogeneic Stem Cell Transplantation (alloHSCT) for Chronic Lymphocytic Leukemia (CLL) in the Era of Novel AgentsAlan Skarbnik, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- An Innovative Telemedicine Platform to Provide Expert Access to Patients with Chronic Lymphocytic Leukemia (CLL)Alan Skarbnik, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- Phase I/II Study of Escalating Doses of Thalidomide in Conjunction with Bortezomib and High Dose Melphalan As a Conditioning Regimen for Autologous Stem Cell Transplan...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Elevated IL-1Ra Levels in the Stem Cell Product Is Associated with the Development of Engraftment Syndrome Following Autologous Stem Cell Transplantation for the Treat...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Safety and Efficacy Data for Combined Checkpoint Inhibition with Ipilimumab (Ipi) and Nivolumab (Nivo) As Consolidation Following Autologous Stem Cell Transplantation ...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Professional Memberships
- Member
- Member
- American Society of Blood and Marrow TransplantationMember
Other Languages
- Portuguese, Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
